Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

We recently published 10 Best Biotech Stocks to Buy Under $10. Recursion Pharmaceuticals, Inc. is placed eighth among them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage ...

84% of developers surveyed by Stack Overflow either use or plan to use AI tools, while 64% cited ‘almost right’ AI output and debugging AI code as their top frustrations. While the number of ...

Stack Overflow: Stark Increase in Developers’ Distrust of AI Tools Your email has been sent While 84% of developers now use AI tools, 46% say they do not trust the accuracy of the tool’s output, ...

More developers than ever before are using AI tools to both assist and generate code. While enterprise AI adoption accelerates, new data from Stack Overflow's 2025 Developer Survey exposes a critical ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

It would be easy to say that artificial intelligence killed off Stack Overflow, but it would be truer to say that AI delivered the final blow. What really happened is a parable of human community and ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...